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Abstract 
Background 
Many parts of Africa have witnessed reductions in Plasmodium falciparum transmission and 
associated mortality over the last 15 years.  Since immunity to malaria is acquired more rapidly 
at higher transmission, the slower acquisition of immunity at lower transmission may partially 
offset the benefits of reductions in transmission. We examined the clinical spectrum of disease 
and predictors of mortality after sustained changes in transmission intensity, using data from 
1989 to 2016. 
Methods 
We conducted a temporal observational analysis of 18,000 children, aged 14 days to 14 years 
old, who were admitted to Kilifi County Hospital, Kenya from 1989 to 2016 with malaria. We 
describe the trends over time of the clinical and laboratory criteria for severe malaria and 
associated risk of mortality. 
Results 
During the time periods 1989-2003; 2004-2008; and 2009-2016, Kilifi County Hospital admitted 
averages of 657, 310 and 174 cases of severe malaria per year including averages of 48, 14 and 
12 malaria-associated deaths per year, respectively.  The median ages in years of children 
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admitted with cerebral malaria, severe anaemia and malaria-associated mortality were 3.0 
(95% confidence interval (CI) 2.2-3.9), 1.1 (95% CI 0.9-1.4), and 1.1 (95% CI 0.3-2.2) in the year 
1989, rising to 4.9 (95% CI 3.9-5.9), 3.8 (95% CI 2.5-7.1) and 5 (95% CI 3.3-6.3) in the year 2016.  
The ratio of children with cerebral malaria to severe anaemia rose from 1:2 before 2004 to 3:2 
after 2009. Hyperparasitaemia was a risk factor for death after 2009 but not in earlier time 
periods. 
Conclusion 
Despite the evidence of slower acquisition of immunity, continued reductions in the numbers of 
cases of severe malaria resulted in lower overall mortality. Our temporal data are limited to a 
single site, albeit potentially applicable to a secular trend present in many parts of Africa. 
Keywords 
Severe malaria, secular trend, mortality, Africa, longitudinal surveillance  
Introduction 
Plasmodium falciparum malaria is an important cause of childhood morbidity and mortality in 
sub-Saharan Africa (sSA), which accounts for 90% of the world’s malaria deaths [1]. Most 
malaria episodes are successfully treated without hospital admission, but a small proportion of 
children are admitted to hospital for severe complications which may include coma (i.e. 
cerebral malaria), severe anaemia (necessitating urgent blood transfusion) or deep breathing 
(due to severe metabolic acidosis) [2, 3].  Globally, unprecedented reductions in Plasmodium 
falciparum transmission were observed from 2000 to 2010, but progress has stalled since 2010 
[4] and the global mortality from malaria may now be increasing [1]. 
Immunity to clinical malaria is acquired following repeated exposure to malaria parasites.  In 
high transmission areas significant clinical malaria is rare after 5 years of age, owing to 
acquisition of immunity in early childhood.  In low transmission areas clinical malaria continues 
to occur at older ages [5], and case fatality may be higher at older age [6].  The dominant severe 
malaria phenotype in areas of low transmission is cerebral malaria rather than severe anaemia 
[5].  Cerebral malaria is associated with higher case fatality than severe anaemia, even when 
the most effective anti-malarial treatment artesunate is used [7, 8].  As many parts of sSA 
approach lower transmission intensities, the changing clinical spectrum of severe malaria could 
potentially offset some of the gains in mortality that would otherwise be expected by improved 
malaria control [9]. 
In this paper we report the trends of severe malaria in Kilifi County Hospital.  We relate the 
trends to trends in transmission intensity previously observed using parasite prevalence surveys 
in the community. A decline in transmission is evidenced 2000 and 2010 in many parts of Africa 
[4].  Detailed analysis of community surveys on the Kenyan Coast show that this recent decline 
began in the mid-1990s, and that transmission increased again after 2010 [10].  In Kilifi County 
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a consistent trend was seen using yearly parasite prevalences from children admitted with 
trauma (as a proxy for community parasite prevalence) [11]. 
We previously reported reduced mortality and morbidity during the period of declining malaria 
transmission in Kilifi County Hospital (KCH) in Coastal Kenya from 1989-2008 [12].  
Subsequently we reported increases in the proportion of children admitted to hospital with 
malaria infection from 2009 to 2014, with older children accounting for much of this increase 
[11].  We now report outcomes to 2016 including detailed data on mortality, clinical features 
and predictors of case fatality. 
Methods 
Since May 1989 there has been continuous surveillance of hospital admissions at KCH as a 
partnership between the Research Programme and Kilifi County Department of Health. Consent 
for the use of data is sought from the parents or legal guardians of admitted children, and wider 
community engagement to explain research activity was undertaken [13].  Linkage to the Kilifi 
Health and Demographic Surveillance System (KHDSS) was established in 2002[14].  At the 
midpoint of the surveillance period, the KHDSS comprised 250,000 residents, including 46,000 
children below 5 years of age and 110,000 children below 14 years of age.  Malaria control 
activities include distributions of insecticide treated bed nets [15], but no indoor residual 
spraying. The malaria vaccine RTS,S was tested in clinical trials but has not been used routinely 
[16, 17]. 
Clinical Surveillance 
The pediatric service at KCH includes two wards; a 70-bed general ward and a 15-bed high 
dependency unit (HDU) staffed by research clinicians and nurses.  The HDU admits children with 
serious illness requiring more intensive monitoring and management (albeit without 
mechanical ventilation facilities). Structured case record are completed electronically on all 
admissions, capturing age, residence, vital signs, clinical history and examination, and the 
Blantyre coma score [18]. Data are linked to the KHDSS database. All admissions routinely have 
a malaria blood slide, full blood count, blood glucose, blood culture investigations. An extended 
biochemical screen, including blood gases, is included for children with severe illness. Ward 
clinicians review the hospital notes on discharge and assign one or two diagnostic terms. 
Inpatient treatment for malaria was parenteral quinine between 1989 and 2010. In 2010 
parenteral treatment was changed to artesunate [7].  When children were able to take oral 
medication, this was chloroquine until 1998, then sulfadoxine/ pyramethamine until 2003, 
amodiaquine until 2005, and then artemether/ lumefantrine to date. 
Definitions 
Severe P. falciparum malaria was defined as per the WHO definition [19] as a positive malaria 
slide with parasitaemia above 2,500 parasites/µl with any one of the following: a) cerebral 
malaria (defined as Blantyre coma score of < 3); b) severe malaria anaemia (defined as 
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hemoglobin concentration less than 5 g/dL); c) respiratory distress (defined as deep breathing); 
d) prostration (defined as inability to stand in children who can usually stand, inability to sit in 
children who cannot usually stand but can sit, or inability to breastfeed in children who cannot 
usually do sit or stand); e) multiple convulsions (defined as two or more convulsions in the 24-
hour period prior to admission) f) jaundice (defined clinically); g) compensated shock (defined 
by age-specific increases in heart rate (in beats per minute (bpm) >180 for children <12 months 
of age; bpm>160 for 12 months to 5 years of age; and bpm>140 for children >5 years of age) 
plus a capillary refill time of >2 seconds; h) decompensated shock (defined as systolic blood 
pressure < 50 mmHg); i) kidney injury (defined according to age-specific pRIFLE criteria to 
calculate estimated glomerular filtration rates[20], using actual height and weight where 
available, and imputing an age-specific average height and weight for where these were not 
measured); j) hypoglycemia (defined as glucose<2.2 mmol/l in accordance with WHO 
guidelines, although a threshold of 3 mmol/l was used for clinical management); k) 
hyperparasitaemia (defined as parasite density >250,000 parasites per µl). 
In this analysis malaria parasite status was retrospectively defined as positive if any of three 
slides taken over the first 3 days of admission were positive for P. falciparum, and the highest 
parasite density of these was used in analysis.  Malaria mortality was defined as inpatient death 
in association with a positive malaria slide.  We refer to mortality when describing absolute 
numbers of children dying with malaria, and case fatality when describing the proportion of 
deaths among those admitted. 
Analysis  
The analysis in this study runs from May 1989 to December 2016 and was restricted to children 
aged 14 days to 14 years of age.  STATA software was used (Version 15.0, College Station, TX: 
StataCorp; 2017). The binomial method was used to calculate 95% confidence intervals for 
median ages, Kruskal-wallis to compare median ages by year restricted to subgroups of children 
with severe malaria. Logistic regression was used to examine risk of death, including all children 
admitted with a positive malaria slide. Three time-periods were defined: 1989-2003; 2004-
2008; and 2009-2016; covering before, during, and after the reduction in malaria cases, 
respectively [11].  In community surveys declining transmission was documented beginning in 
the mid-90s {Snow, 2015 #2303}, and hence preceded the declines observed in clinical cases. 
We justify these three time periods as corresponding to the clinical manifestations, which have 
a non-linear relationship with transmission intensity{Snow, 1997 #641}{Okiro, 2009 #857}.  
Models were developed as follows: univariable analyses; multivariable analysis of all covariates; 
backwards exclusion of non-significant associations (i.e. p>0.05) excepting the three major 
grouping of severe malaria, age and time-period which were maintained regardless of 
significance; then adding interactions between covariates and time (excluding those for which 
p>0.05). 
Asymptomatic parasitaemia is frequent in malaria endemic regions and clinical features of 
severe malaria overlap with other common causes of admission.  This is countered by 
5 
 
restricting analysis to parasitaemia above 2,500 parasites/µl, as described above [21].  As a 
sensitivity analysis we re-ran all analyses including malaria parasitaemia at any density, but 
restricting to children where “malaria” was used among the top two clinical diagnostic terms 
assigned by clinicians reviewing the clinical records after discharge (supplementary material 
only).  We also conducted a sub-analysis included only children resident in the KHDSS, which 
provided denominators in order to calculate incidences. 
Results  
Between 6th May 1989 and 31st December 2016 there were 116,056 pediatric admissions, of 
whom 99,126 (85.4%) children were aged 14 days to 14 years of age.  Of these children, 17,691 
(17.8%) showed one or more criteria for severe malaria, of whom 12,805 (72.3%) had a parasite 
count of >2,500/µl.  Annual pediatric admissions to KCH varied, from 3,886 in the mid-1990s to 
a high of 4700 in the year 2000 before falling to 2,986 in 2014 (Supplementary Figure 1).   
Trends in Severe Malaria Cases 
The number of severe malaria cases peaked in 1999.  However, this apparent peak coincides 
with improved data collection on the full range of signs and symptoms of severe malaria in 
1999 (panels d, e of Figure 1 and Supplementary Figure 1).  Data collection was consistent from 
2000 onwards, hence the declining trend after 2000 to a nadir in 2009 and then the subsequent 
slight increase through to 2016 are not associated with changing patterns in data collection 
(Supplementary Figure 2). 
The period 1989 to 2003 included averages of 657 cases of severe malaria per year and 48 
malaria-associated deaths per year.  From 2004 to 2008 there were averages of 310 cases and 
14 deaths per year, and from 2009 to 2016 there were 174 cases and 12 deaths per year. The 
absolute numbers of non-severe malaria admissions fell more year-on-year than the absolute 
numbers of severe malaria admissions, hence there was a general trend for an increasing 
proportion of all admissions with one or more criteria for severe malaria increased year-on-
year. 
Criteria for Severe Malaria 
There were averages of 85, 62 and 44 cases of cerebral malaria per year with 14 (16%), 10 
(16%) and 8 (18%) deaths in the periods 1989-2003; 2004-2008; and 2009-2016, respectively. 
The ratio of children with cerebral malaria to severe anaemia gradually changed from 1:2 
before 2004 to 3:2 after 2009 (Figure 1).  Respiratory distress, hypoglycaemia, 
hyperparasitaemia and multiple convulsions were experienced by >10% of children, but 
jaundice, kidney injury and compensated shock were uncommon (i.e. <5%), with almost no 
cases of decompensated shock.  There was no observed variation in the proportion of children 
with malaria showing these additional signs over time excepting the increase since in 1999 
which coincided with improved data collection (Supplementary Figure 2). 
Incidence among Residents of KHDSS Area 
6 
 
Similar trends in clinical features and mortality were seen when data were restricted to children 
resident within the KHDSS area, allowing incidence rates to be computed.  The incidence of 
severe disease fell from 7.9 per 1,000 in 2003 to 1.6 per 1,000 in 2015.  Cerebral disease fell 
from 1.3 per 1,000 in 2003 to a low of 0.1 per 1000 in 2008, but then increased to 0.5 per 1,000 
in 2015 (Supplementary Figure 3).   
Trends in Median Age 
We studied median ages of children with different clinical features of malaria as an indication of 
the relative susceptibilities of older vs younger children (Figure 2).   
In 1989 the median ages of children in the following groups: a) hospitalized without malaria; b) 
with severe malaria anaemia; and c) with cerebral malaria were: a) 1.1 years (95% CI 1.0-1.2); b) 
1.1 years (95% CI 0.9-1.4) and c) 3.0 years (95% CI 2.2-3.9), respectively.  By the year 2016 the 
median ages were: a) 1.8 years (95% CI 1.7-1.9); b) 3.8 years (95% CI 2.5-7.1) and c) 4.9 years 
(95% CI 3.9-5.9), respectively.  Hence there were slight increases in median ages among 
children hospitalized without malaria, but marked increases among children hospitalized with 
severe anaemia and cerebral malaria (p<0.0001 for comparison of 1989 with 2016).  
Among children dying with and without malaria, the median ages in 1989 were 1.1 years (95% 
CI 0.3-2.2) and 1.4 years (95% CI 0.9-1.8), respectively rising by 2016 to 5 years (95% CI 3.3-6.3) 
and 1.2 years (95% CI 1-1.3).  Similar results were seen using the alternate case definition 
(Supplementary Figure 4). 
Case Fatality 
Univariable analysis demonstrated that all the criteria tested for severe malaria were 
associated with increased risk of mortality excepting prostration (Table 1).  On multivariable 
analysis including all factors the independent predictors of case fatality were cerebral malaria, 
respiratory distress, severe anaemia, acidosis, kidney injury and hypoglycaemia (“Multivariable 
(all variables)” in Table 1).  We therefore restricted further multivariable analysis to the 
statistically significant criteria for clinical malaria, also retaining time period, age and 
cerebral/respiratory distress/severe anaemia as predictors (“Multivariable (restricted) in Table 
1).   
We selected interactions to consider for the final model by examined the unadjusted 
interactions between criteria for severe malaria and time period (Supplementary Table 2). 
Adjusted interactions were not significant between time and acidosis (p=0.8), cerebral malaria 
(p=0.7), age (p=0.6), compensated shock (p=0.7) and hypoglycaemia (p=0.5) and respiratory 
distress (p=0.7), and therefore not included in the final model.  The adjusted interaction was 
statistically significant for hyperparasitaemia (p=0.001), which was retained for the final 
interaction model.  Age and time-period did not show a significant interaction (p=0.7), 
indicating that the case fatality for a given age and phenotype was consistent over time.   
7 
 
Akaike’s Information Criteria scores were 812.2 for the multivariable (all variables) model, 804.7 
for the multivariable (restricted) model and 803.6 for the interaction model with 13, 9 and 11 
degrees of freedom, respectively. 
Increasing age was associated reduced mortality on univariable analysis but not after adjusting.  
Within time period, there was reduced mortality during the decline in univariable and restricted 
multivariable analysis, but not after adjusting in the interaction model.  After the decline (i.e. 
2009-16) there was a slight, but statistically non-significant increase in mortality on unadjusted 
analysis which was not evident after adjusting. Using the alternate case definition based on 
clinical judgement (Supplementary Table 3,4) the post-decline increase in mortality was 
significant when unadjusted, but again was not significant after adjusting (Supplementary Table 
4).   
Discussion   
Over 27 years of continuous longitudinal surveillance we show substantial changes in the 
numbers of admissions to hospital with severe malaria and in mortality.  We previously 
reported detailed the epidemiological transition to the nadir of severe malaria cases in 2009 
[12], and reported spatial and temporal distributions of malaria slide positivity through to 
2014{Mogeni, 2016 #2682}.  These updated data show the longer-term outcomes with more 
detailed clinical categorization through to 2016 [4, 24]. 
 
The increasing median ages among children with severe anaemia, with cerebral malaria, and 
with malaria-associated mortality suggest that children at later time periods had less immunity 
than would have been the case at earlier time periods, and hence a population of older children 
had emerged with susceptibility to severe malaria.  In 1989 severe malaria was largely limited 
to children under 5 years of age. In 2016 half of all children with severe malaria were above 5 
years of age.  Immunological studies in Kilifi report reduced titres of anti-malaria antibodies as 
transmission declines [25]. 
 
What impact does lowered immunity have on case fatality?  Predictors of case fatality remained 
constant over time, with the exception of hyperparasitaemia which emerged as a risk factor for 
case fatality after 2009.  Cerebral malaria carries a high case fatality [8].  The increasing 
proportion of children with cerebral malaria and the emergence of hyperparasitaemia as a risk 
factor will lead to an increase in overall case fatality, and therefore could be expected to lead to 
increased mortality. However, although numbers of cerebral malaria cases increased, overall 
numbers of admissions with severe malaria fell, hence there was no increase in absolute 
mortality.   
There was a statistically non-significant increase in case fatality after 2009 in primary analysis 
(Table 1), although this was statistically significant using the alternate case definition on clinical 
criteria (Supplementary Table 4).  In both cases this increase was accounted for by adjusting for 
other factors, and likely relates to the increased case fatality seen in cerebral malaria. There 
was no indication that case fatality among specific sub-groups increased after 2009 with the 
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exception of hyperparasitaemia.  This finding was the only evidence that waning immunity 
might have a detrimental impact on case fatality.  It is possible that other trends countered the 
potential impact on case fatality such as improved medical care with intravenous artesunate in 
2010 [7] or improved fluid management [27]. 
The study has limitations. Data were incomplete, particularly for the presence of multiple 
convulsions, although this was not an independent predictor of mortality.  Secular trends may 
confound our analysis.  Improved medical management has already been mentioned, and 
improved access to community and/or hospital healthcare is likely to impact the frequency 
and/or severity of presentation with malaria.  The population has increased over time.  While 
fertility rates are falling, increasing child survival and changes in hospital usage might have 
impacts on the median age of children coming to the hospital.  There was a trend of increasing 
age among children without malaria, but not among children admitted whose admission ended 
in death (Figure 2), suggesting that the increases in median age among children with malaria 
are not due to a general trend impacting the wider population. 
The definition of severe malaria is non-specific when asymptomatic parasitaemia coincides with 
severe illness of non-malarial etiology [21].  This was mitigated by two different case 
definitions: a) including a parasite density threshold b) restricting analysis to those children in 
whom clinicians had confirmed a discharge diagnosis of malaria.  Our definitions of severe 
malarial anaemia and cerebral malaria followed the WHO definition [23], but could have been 
refined using additional clinical criteria [8, 28] and retinal examination [29], which we did not 
conduct. 
Conclusion 
Our data indicate one possible outcome of a secular trend of reducing malaria transmission 
followed by stagnation, and this secular trend seems to be widespread in many parts of Africa 
[4].  Investment in data collection in routine settings is essential to more widely describe the 
outcomes of changes in malaria transmission and access to care, and offers a cost-effective and 
scalable solution to malaria monitoring. 
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Table 1: Univariable and Multivariable Logistic Regression Models for Risk of Mortality in Severe 
Malaria (Case Definition Includes the >2,500 parasites per µl Threshold.) 
 
Footnote: Odds Ratios (ORs) are shown with 95% confidence intervals in brackets.  Interaction 
terms are not relevant to univariable models.  “NA” is shown for cells where the model was not 
applicable, and “-“ is shown for cells with insufficient data (occurring where multiple seizures 
and other covariates were not collected between 2004 to 2009). Multivariable (restricted) 
refers to a model where non-significant predictors were excluded from the model.    
Predictors Univariable Multivariable (all variables) Multivariable (restricted) Interaction model 
  Odds Ratio P value Odds Ratio P value Odds Ratio P value Odds Ratio P value 
Time (1989-1999) Reference 
      
Time (2004-2008) .7 (.55 to .9) 0.005 NA NA .68 (.48 to .97) 0.03 .8 (.53 to 1.2) 0.28 
Time (2009-2016) 1.09 (.88 to 1.37) 0.43 .75 (.46 to 1.24) 0.26 1.05 (.68 to 1.6) 0.83 .8 (.48 to 1.32) 0.38 
Acidosis 7.07 (5.77 to 8.67) <0.0001 3.31 (2.09 to 5.25) <0.0001 2.75 (2.01 to 3.76) <0.0001 2.83 (2.06 to 3.89) <0.0001 
Age (years) .96 (.93 to .99) 0.02 1.08 (.98 to 1.18) 0.11 1.05 (.98 to 1.12) 0.19 1.05 (.98 to 1.13) 0.16 
Cerebral 7.63 (6.59 to 8.83) <0.0001 3.81 (2.54 to 5.74) <0.0001 4.21 (3.17 to 5.57) <0.0001 4.38 (3.3 to 5.82) <0.0001 
Compensated 
Shock 
4.76 (3.4 to 6.66) <0.0001 1.03 (.47 to 2.23) 0.94 NA NA NA NA 
Hyperparasitaemia 1.19 (1.02 to 1.38) 0.03 .89 (.58 to 1.37) 0.6 NA NA .75 (.51 to 1.09) 0.13 
Hypoglycaemia 8.81 (6.98 to 11.1) <0.0001 1.93 (1.17 to 3.2) 0.01 3 (2.17 to 4.14) <0.0001 3.2 (2.3 to 4.45) <0.0001 
Kidney Injury 6.09 (4.43 to 8.37) <0.0001 2.45 (1.29 to 4.63) 0.006 2.76 (1.79 to 4.25) <0.0001 2.64 (1.71 to 4.09) <0.0001 
Mx Convulsions 2.21 (1.67 to 2.92) <0.0001 .92 (.56 to 1.51) 0.75 NA NA NA NA 
Jaundice 2.43 (1.49 to 3.98) 0.0004 .87 (.31 to 2.49) 0.8 NA NA NA NA 
Prostration 1.05 (.71 to 1.56) 0.81 NA NA NA NA NA NA 
Resp. Distress 9.41 (7.69 to 11.5) <0.0001 2.23 (1.45 to 3.42) 0.0002 1.92 (1.42 to 2.6) <0.0001 1.95 (1.44 to 2.65) <0.0001 
Severe Anaemia 2.24 (1.93 to 2.6) <0.0001 1.25 (.78 to 1.99) 0.35 1.1 (.78 to 1.54) 0.59 1.08 (.77 to 1.52) 0.66 
Time (2004-2008) * Hyperparasitaemia NA NA NA NA .63 (.29 to 1.34) 0.23 
Time (2009-2016) * Hyperparasitaemia NA NA NA NA 2.53 (1.07 to 5.97) 0.03 
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Figure 1: Trends in Mortality and Clinical Features of Severe Malaria over Time. 
 
Figure legend 1: The trends over time are shown for clinical features of severe malaria among 
all children admitted with a parasite threshold of >2500 µl.  The % of children with a parasite 
threshold >2500/µl where the relevant observation was positive is shown in red bars (left y 
axis); and the absolute number of cases where the observation was positive is shown by the 
blue line (right y axis). 
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Figure 2: Median Ages for Children Admitted to Kilifi County Hospital 
 
Figure Legend 2: Median ages of presentation to hospital for specific phenotypes (see color 
legend) are shown over time with 95% confidence intervals calculated by the binomial exact 
method. 
 
Supplementary Table 1: Frequency of Mortality and Criteria for Severe Malaria by Year 
 
Supplementary Table 2: Unadjusted Logistic Regression for Risk of Death by Time Period.  Case 
Definition Includes Parasite Density threshold (i.e. >2,500 Parasites Per µl).  
 
Supplementary Table 3: Unadjusted Logistic Regression for Risk of Death by Time Period.  Case 
Definition Includes Diagnosis by Clinician.  
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Supplementary Table 4: Univariate and Multivariate Logistic Regression Models for Risk of 
Mortality in Severe Malaria. Case Definition Includes Diagnosis by Clinician. 
 
Supplementary Figure 1: Numbers of admissions to Kilifi County Hospital over time.  
 
Supplementary Figure 2: Trends in Mortality, Full Clinical Features of Severe Malaria and 
Completeness of Data Collection over Time. 
 
Supplementary Figure 3: Trends in Incidence of Mortality and Clinical Features of Severe 
Malaria over Time for Kilifi Health and Demographic Surveillance System Residents. 
 
Supplementary Figure 4: Median Ages for Children Admitted to Kilifi County Hospital. Case 
Definition Includes Diagnosis by Clinician.  
 
Supplementary Figure 5: Adjusted Case Fatality Rates in Kilifi and in the AQUAMAT and SMAC 
studies.  
 
